- Home
- ODD vs IBRX Comparison
ODD vs IBRX Comparison
Compare ODD & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- IBRX
- Stock Information
- Founded
- ODD 2018
- IBRX 2014
- Country
- ODD Israel
- IBRX United States
- Employees
- ODD N/A
- IBRX N/A
- Industry
- ODD
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODD
- IBRX Health Care
- Exchange
- ODD Nasdaq
- IBRX Nasdaq
- Market Cap
- ODD 2.3B
- IBRX 2.4B
- IPO Year
- ODD 2023
- IBRX N/A
- Fundamental
- Price
- ODD $71.00
- IBRX $2.07
- Analyst Decision
- ODD Buy
- IBRX Strong Buy
- Analyst Count
- ODD 8
- IBRX 5
- Target Price
- ODD $54.63
- IBRX $11.35
- AVG Volume (30 Days)
- ODD 1.1M
- IBRX 8.6M
- Earning Date
- ODD 04-29-2025
- IBRX 05-16-2025
- Dividend Yield
- ODD N/A
- IBRX N/A
- EPS Growth
- ODD 45.36
- IBRX N/A
- EPS
- ODD 1.74
- IBRX N/A
- Revenue
- ODD $703,488,000.00
- IBRX $14,745,000.00
- Revenue This Year
- ODD $22.39
- IBRX $579.28
- Revenue Next Year
- ODD $20.09
- IBRX $179.96
- P/E Ratio
- ODD $40.82
- IBRX N/A
- Revenue Growth
- ODD 26.83
- IBRX 2270.58
- 52 Week Low
- ODD $32.71
- IBRX $1.83
- 52 Week High
- ODD $69.96
- IBRX $9.16
- Technical
- Relative Strength Index (RSI)
- ODD 84.66
- IBRX 36.78
- Support Level
- ODD $39.55
- IBRX $1.83
- Resistance Level
- ODD $43.14
- IBRX $2.63
- Average True Range (ATR)
- ODD 3.73
- IBRX 0.19
- MACD
- ODD 2.35
- IBRX -0.05
- Stochastic Oscillator
- ODD 99.78
- IBRX 23.08
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.